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lower than the highest GNI-graduating 
country.4 
Therefore, it is important for 
the public health community to 
aggressively use several strategies to 
address the underlying deﬁ ciencies in 
the vaccine market. These strategies 
include, as Berkley notes, demand 
forecasting and pooled procurement, 
but they also must include 
collaboration between agencies and 
governments to eﬀ ectively negotiate 
with manufacturers, and investment 
to broaden the manufacturing base, 
thus promoting competition and a 
broader supply base. Transparency 
around research and development 
and manufacturing costs, as well as 
vaccine pricing, will be important 
to help realise this change. Pricing 
must be set in a fair way that both 
rewards innovation and ensures that 
cash-strapped health systems can 
ultimately afford products beyond 
donor support.
Lastly, the question of who should 
be governing the search for solutions 
is also essential. GAVI and other 
stakeholders can have a critical role 
but it is vital that governments, 
including key emerging economies, 
are the drivers of future eﬀ ort. It is 
only in this way that all stakeholders 
can feel confident in buying into a 
new global strategy.
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association between nursing resources 
and patient outcomes.
Masako Sugihara raises the 
important issue of nurse turnover. 
Administrative data on hospital nurse 
turnover are not available in Europe. 
However, we created proxy measures 
of turnover by calculating the percent 
of nurses surveyed with intentions to 
leave within a year, and alternately the 
percent of nurses employed for less than 
2 years. Neither measure is signiﬁ cantly 
related to percent of bachelor’s nurses 
or nurse workloads, nor are they related 
to mortality. They would have to be 
related to both nursing factors and 
mortality to alter the eﬀ ects we ﬁ nd. 
Importantly, patients are less satisﬁ ed 
with care in hospitals in which a larger 
proportion of nurses intend to leave,6 
and turnover contributes to nurse 
shortage, making this nurse turnover a 
matter of policy concern.
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Is tiered pricing the way 
for vaccines?
S e t h  B e r k l e y ’s  V i e w p o i n t 
(June 28, p 2265)1 on improving 
access to vaccines through tiered 
pricing touches on important issues. 
Berkley identiﬁ es two key challenges 
for the global vaccination community: 
concerns about the sustainability 
of immunisation programmes in 
countries that will graduate from GAVI 
support2 and the high price that many 
countries, especially middle-income 
countries, and vaccine providers, like 
Médecins Sans Frontières (MSF), have 
to pay for newer vaccines. These are 
issues that push us, as a public health 
community, in considering how to 
achieve equity. 
Berkley’s proposal of tiered pricing 
as the solution, however, is deﬁ cient 
for several reasons. The general 
shortcomings of tiered pricing— 
including its inferiority to genuine 
competition, arbitrary divisions 
between populations, and the lack of 
transparency on price setting—have 
been documented.3 Berkley notes that 
tiered pricing already exists and has 
been credited with lowering prices paid 
by the GAVI Alliance for the world’s 
poorest countries. The negative eﬀ ects 
of the tiered pricing system will also 
be seen, however, as countries face 
the double challenge of losing GAVI 
subsidies to pay for costly vaccines 
and, as Berkley notes, “that they 
[graduating countries] could be at risk 
of suspending vaccination programmes 
because they face a so-called pricing 
cliff, with steep increases when they 
no longer have access to GAVI prices.”1 
Furthermore, gross national income 
(GNI)—the often-suggested criterion 
for establishing tiers and which 
determines GAVI eligibility—is an 
unsophisticated measure of country 
welfare and inappropriate from a public 
health perspective. There are currently 
20 countries graduating from GAVI 
support (more than 25% of the total 
supported), 28 countries that have 
never been GAVI-eligible have a GNI 
